Intellia Therapeutics Inc (NASDAQ:NTLA) has received an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $34.10.
Several brokerages have issued reports on NTLA. Raymond James began coverage on shares of Intellia Therapeutics in a research note on Thursday, September 20th. They issued a “market perform” rating on the stock. Zacks Investment Research cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. BidaskClub cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Credit Suisse Group began coverage on shares of Intellia Therapeutics in a research note on Monday, October 29th. They issued a “neutral” rating and a $24.00 price objective on the stock. Finally, Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Thursday, October 18th.
Shares of Intellia Therapeutics stock opened at $17.91 on Monday. The firm has a market capitalization of $777.64 million, a PE ratio of -9.53 and a beta of 3.88. Intellia Therapeutics has a 12 month low of $15.70 and a 12 month high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Wednesday, October 31st. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). The business had revenue of $7.41 million during the quarter, compared to analyst estimates of $11.58 million. Intellia Therapeutics had a negative net margin of 308.81% and a negative return on equity of 31.70%. The business’s revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) earnings per share. Analysts predict that Intellia Therapeutics will post -2.09 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. Macquarie Group Ltd. purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter worth $101,000. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $116,000. Nikko Asset Management Americas Inc. purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $141,000. Legal & General Group Plc boosted its position in shares of Intellia Therapeutics by 75.4% during the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after purchasing an additional 2,333 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Intellia Therapeutics by 519.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock worth $157,000 after purchasing an additional 4,807 shares in the last quarter. 67.80% of the stock is currently owned by institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Article: How dollar cost averaging works
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.